Tye1001 is a targeted anticancer conjugate drug that involves the coupling of a highly active and toxic small molecule toxin with a specific drug carrier.
Tyercan
Tye1002 is a peptide-conjugate drug targeting the classical somatostatin receptor type 2 (SSTR2, SST2).
Tyercan
Tye1014 is a targeted therapeutic agent conjugated with a highly active mitotic inhibitor. It effectively suppresses the growth of various tumor cells, demonstrating particularly robust anti-tumor effects, with promising clinical applications, especially in Small Cell Lung Cancer (SCLC).
Tyercan
Targeting CDK (Cyclin-Dependent Kinase) and developing CDK inhibitors has consistently been a focal point in the research and development of anti-tumor drugs
Tyercan
Tye2001 is also a peptide-conjugated drug targeting the classical somatostatin receptor type 2 (SSTR2, SST2). SSTR2 is highly expressed in immune cells at inflammatory sites and in immune cells associated with certain autoimmune diseases
Tyercan
Tyercan is a biopharmaceutical company established by an international team of drug experts and is located in the Pingshan District Biomedical Innovation Industrial Park in Shenzhen.
Tyercan
From November 22 to 24, 2022, the three-day expert final review meeting of the Science and Technology China Innovation and Venture Capital Conference was held in Shenzhen With the theme of Smart China and Lighting Up Dreams, six major industries collecte
Celebrating the first phase of the Shenzhen, Hong Kong, Macao and Taiwanese women project roadshow was successfully held on November 17, 2022 The first phase of the Shenzhen, Hong Kong, Macao and Taiwanese women project selection roadshow with the theme
From November 15th to 19th, 2022, the China International High-tech Fair (hereinafter referred to as the Hi-Tech Fair) was successfully held in Futian District, Shenzhen Nata, Vice President of Shenzhen Taierkang Biomedical Technology Co , Ltd was speci
On November 10-11, 2022, the 24th Shanghai International Biotechnology and Medicine Symposium (BIO-FORUM) series of China biotechnology and medicine innovation forums was grandly held in Shanghai The conference announced Xingyao at the same time
At 14:00 on October 17, 2022, the life health and biological sciences theme lecture hosted by Shenzhen Taierkang Biomedical Technology Co , Ltd was successfully held in the conference room on the 4th floor of Building 4, Pingshan National Pharmaceutical
After Dr Natalya Vasilevich joined Telcon, the company once again introduced Russian expert Dr Alexander V Chestkov Dr Alexander serves as Telcon s R&D Director!
Let us work together to create brilliance!
Tel: +86-755-84517304
E-mail: Office@tyercan.com
Address: No. 901, 9th Floor, Building 10, Shenzhen Biomedical Innovation Industrial Park, No. 14 Jinhui Road, Kengzi Street, Pingshan District, Shenzhen
Shanghai office: Room C16, 2nd Floor, Tower A, Phase 2, Fenglin International Building, No. 420 Fenglin Road, Xuhui District, Shanghai
